Addressing adolescent substance use with a public health prevention framework: the case for harm reduction
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Adolescence is a developmental stage defined in part by risk-taking. Risk-taking is critical to normal development and has important benefits including trying new activities and exploring new relationships. Risk-taking is also associated with the initiation of substance use. Because substance use often begins in adolescence, much focus has been on primary prevention with the goal of preventing initial substance use. Secondary or tertiary prevention approaches, such as counselling to eliminate substance use or offering treatment, are common approaches for adolescents with problematic substance use or a substance use disorder. While this is important, for some adolescents, treatment or cessation of use may not be desired. In these cases, Healthcare Practitioners (HCPs) can offer clear advice that incorporates harm reduction. Harm reduction, which is often applied for adults who use substances, reduces the negative impacts associated with drug use without requiring abstinence. Harm reduction is crucial to keeping adolescents safe and healthy and can offer opportunities for future engagement in treatment. The objective of this review is to describe strategies for integrating harm reduction principles in clinical settings that are developmentally appropriate. A patient-centered, harm reduction approach can validate perceived benefits of substance use, offer strategies to minimise harm, and advise reduction of use and abstinence.KEY MESSAGES:Substance use often begins in adolescence and traditional approaches are often rooted in prevention framework.Harm reduction should be incorporated for adolescents with problematic substance use or a substance use disorder.This review offers strategies for integration of harm reduction principles tailored towards adolescents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neurobiology of addiction: a neurocircuitry analysis
Koob, G. F., & Volkow, N. D. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)00104-8 · Cited by 3,698 · cited 1×
“Focussing on education around risk is an important and valid approach given the known impact that substance use has on brain development and functioning in addition to the association of the adverse consequences of substance use [20].”
BackgroundSordo, L., Barrio, G., Bravo, M. J., Indave, B. I., Degenhardt, L., Wiessing, L., Ferri, M., & Pastor-Barriuso, R. (2017) · BMJ · doi:10.1136/bmj.j1550 · Cited by 1,816 · cited 1×
“In adults, treatment with buprenorphine and methadone is associated with reduced all-cause and opioid-related mortality [68,69].”
BackgroundSoneji, S., Barrington-Trimis, J. L., Wills, T. A., Leventhal, A. M., Unger, J. B., Gibson, L. A., Yang, J., Primack, B. A., Andrews, J. A., Miech, R. A., et al. (2017) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2017.1488 · Cited by 1,170
Larochelle, M. R., Bernson, D., Land, T., Stopka, T. J., Wang, N., Xuan, Z., Bagley, S. M., Liebschutz, J. M., & Walley, A. Y. (2018) · Annals of Internal Medicine · doi:10.7326/m17-3107 · Cited by 1,076 · cited 9×
“The current FDA approved MOUD include methadone, buprenorphine, and naltrexone.”
BackgroundInfluentialSelf-citationWalley, A. Y., Xuan, Z., Hackman, H. H., Quinn, E., Doe-Simkins, M., Sorensen-Alawad, A., Ruiz, S., & Ozonoff, A. (2013) · BMJ · doi:10.1136/bmj.f174 · Cited by 999
Park, T. W., Saitz, R., Ganoczy, D., Ilgen, M. A., & Bohnert, A. S. B. (2015) · BMJ · doi:10.1136/bmj.h2698 · Cited by 579
Benzodiazepines revisited—will we ever learn?
Lader, M. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03563.x · Cited by 573
Treatment of Benzodiazepine Dependence
Soyka, M. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1611832 · Cited by 465
Sensitive periods of substance abuse: Early risk for the transition to dependence
Jordan, C. J., & Andersen, S. L. (2017) · Developmental Cognitive Neuroscience · doi:10.1016/j.dcn.2016.10.004 · Cited by 455
Benzodiazepine Use and Misuse Among Adults in the United States
Maust, D. T., Lin, L. A., & Blow, F. C. (2019) · Psychiatric Services · doi:10.1176/appi.ps.201800321 · Cited by 337 · cited 1×
“report prior benzodiazepine exposure [86,87].”
Cited by
Drug overdose deaths with evidence of counterfeit pill use—United States, July 2019–December 2021.
O’Donnell, J., Tanz, L. J., Miller, K. D., Dinwiddie, A. T., Wolff, J., Mital, S., Obiekwe, R., & Mattson, C. L. (2023) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7235a3 · Cited by 58
“Younger persons might also exhibit more risk-taking behaviors than do older persons, and engage less with harm reduction services ( 5 ).”
BackgroundWelsh, J. W., Dopp, A. R., Durham, R. M., Sitar, S. I., Passetti, L. L., Hunter, S. B., Godley, M. D., & Winters, K. C. (2025) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2024.03.010 · Cited by 21
Lee, G., Hicks, D. L., Kedia, S., Regmi, S., & Mou, X. (2024) · Children and Youth Services Review · doi:10.1016/j.childyouth.2024.107456 · Cited by 9
Halladay, J., Stead, V., McCarron, C., Kennedy, M., King, K., Venantius, M., Carter, A., Syan, S., Matthews, M., Khoshroo, S., et al. (2022) · medRxiv · doi:10.1101/2022.10.21.22281362 · Cited by 5
Metadata
- Authors
- Winer, J. M., Yule, A. M., Hadland, S. E., & Bagley, S. M.
- Venue
- Annals of Medicine
- Publisher
- Informa UK Limited
- Published
- 2022-07-28
- Volume
- 54
- Issue
- 1
- Pages
- 2123-2136
- ISSN
- 0785-3890 (ISSN-L)
- 1365-2060
- OpenAlex
- W4288431986
- Cited by
- 58
- References
- 23
- FWCI
- 6.89
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Addressing adolescent substance use with a public health prevention framework: the case for harm reduction. https://app.cochat.ai/papers/10.1080/07853890.2022.2104922
- The paper
- Winer, J. M., Yule, A. M., Hadland, S. E., & Bagley, S. M. (2022). Addressing adolescent substance use with a public health prevention framework: the case for harm reduction. Annals of Medicine. https://doi.org/10.1080/07853890.2022.2104922
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.